Christopher Towers - Oct 4, 2023 Form 4 Insider Report for INTELLIGENT BIO SOLUTIONS INC. (INBS)

Role: Director
Signature: /s/ Christopher Towers
Stock symbol: INBS
Transactions as of: Oct 4, 2023
Transactions value $: $0
Form type: 4
Date filed: 10/6/2023, 06:45 PM
Previous filing: Aug 17, 2023
Next filing: Nov 17, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	INBS	Common Stock	Purchase		+9.09K	+1150.63%		9.88K	Oct 4, 2023	Direct	F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	INBS	Common Stock Warrants (Series E)	Purchase		+9.09K			9.09K	Oct 4, 2023	Common Stock	9.09K		Direct	F1, F2
transaction	INBS	Common Stock Warrants (Series F)	Purchase		+9.09K			9.09K	Oct 4, 2023	Common Stock	9.09K		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported securities are included within 9,090 INBS Class A Units purchased by the reporting person for $0.55 per Unit. Each Unit consists of one share of the common stock, one warrant to purchase one share of Common Stock at an exercise price of $0.55 per share ("Series E Warrants"), and one warrant to purchase one share of Common Stock at an exercise price of $0.55 per share ("Series F Warrants"). The Warrants will be exercisable beginning on the effective date of such stockholder approvals as may be required by the applicable rules and regulations of the Nasdaq Capital Market (or any successor entity) to permit the exercise of the Warrants ("Warrant Stockholder Approval").
F2	The exercise price of the Series E Warrants is $0.55 per share. However, under the one-time reset provision of the Series E Warrants, the exercise price of the Series E Warrants will reset to a price equal to the lesser of (i) the then exercise price and (ii) 90% of the five-day volume weighted average price for the five trading days immediately following the date the Company effects a reverse stock split.
F3	The exercise price of the Series F Warrants is $0.55 per share. However,under the alternate cashless exercise option of the Series F Warrants, the holder of the Series F Warrant (beginning on the date the Warrant Stockholder Approval is effective), has the right to receive an aggregate number of shares of Common Stock on a one-for-one basis (subject to adjustment).
F4	On February 9, 2023, the Issuer effected a 1-for-20 reverse stock split of its common stock (the "Reverse Split"). Unless otherwise noted, the amount of securities and purchase prices reported on this Form 4 have been adjusted to reflect the Reverse Split.